摘要
目的:探讨胸腺肽α1治疗对脑梗死并发重症医院获得性肺炎(SHAP)患者单核细胞人类白细胞抗原DR(HLA-DR)等免疫指标的影响及其临床意义。方法:46例脑梗死并发SHAP患者随机分为治疗组(n=25)和对照组(n=21)。治疗组给予1.6mg胸腺肽α1皮下注射,bid,持续1周。对照组仅对脑梗死和SHAP常规治疗。结果:治疗组治疗后单核细胞HLA-DR、CD4+细胞及CD4+/CD8+比值明显上升,其存活者抗生素应用时间、重症监护病房(ICU)住院时间和机械通气时间均比对照组明显缩短,神经功能缺损的改善亦优于对照组。结论:胸腺肽α1能提高脑梗死并发SHAP患者免疫功能,有利于感染控制。
OBJECTIVE To investigate the ettectsof thymosin alpha 1 on monocyte human leukocyte antigen DR（HLA-DR） and other immune parameters and the clinical significance in patients with acute cerebral infarction（ACI） and severe hospital acquired pneumonia（SHAP）. METHODS A total of 46 patients with ACI and SHAP were randomly divided into 2 groups： the treatment group（n = 25） and the control group （n = 21 ）. All patients received conventional therapy for ACI and SHAP. The treatment group received 1.6 mg of thymosin alpha through subcutaneous injection q 12 h for a week. RESULTS The level of monocyte HLA-DR,CD4 ＋ cell and CD4 ＋/CD8 ＋ ratio increased significantly after treatment in the treatment group. The duration of use of antibiotic injection,ICU stay and mechanical ventilation in survivors of treatment group decreased significantly compared with that in survivors of control group. And the improving of central nervous function in treatment group was better than that in control group. CONCLUSION Thymosin alpha 1 can improve the immune function of patients with ACI and SHAP and is helpful to controlling infection.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2006年第4期390-392,共3页
Chinese Journal of Hospital Pharmacy
关键词
胸腺肽Α1
脑梗死
重症医院获得性肺炎
单核细胞人类白细胞抗原DR
thymosin alpha 1
acute cerebral infaretiom severe hospital acquired pneumonia
monocyte human leukocyte antigen DR
